News Focus
News Focus
icon url

DewDiligence

09/12/10 6:04 PM

#104000 RE: Shengli #103997

I bet [MRK] beat this number easily…

MRK can’t possibly report a Boceprevir SVR rate in null responders that beats Telaprevir’s 31% rate in the REALIZE study because MRK’s RESPOND-2 study explicitly excluded null responders.